董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lawrence Otto Klein | 男 | Director, President and Chief Executive Officer | 44 | 335.61万美元 | 152.24 | 2025-12-11 |
| Samarth Kulkarni | -- | Chairman | -- | 23.41万美元 | 3.57 | 2025-12-11 |
| Kristine M. Ball | -- | Independent Director | -- | 21.31万美元 | 未持股 | 2025-12-11 |
| Peter Harwin | -- | Independent Director | -- | 20.91万美元 | 851.18 | 2025-12-11 |
| Carl Dambkowski | -- | Independent Director | -- | 20.06万美元 | 2.51 | 2025-12-11 |
| Christopher Martin | 男 | Independent Director | 49 | 80.40万美元 | 未持股 | 2025-12-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lawrence Otto Klein | 男 | Director, President and Chief Executive Officer | 44 | 335.61万美元 | 152.24 | 2025-12-11 |
| Laura Sandler | 女 | Chief Operating Officer | 48 | 未披露 | 未持股 | 2025-12-11 |
| Joana Goncalves | -- | Chief Medical Officer | -- | 233.86万美元 | 1.03 | 2025-12-11 |
| Arjun Agarwal | -- | Senior Vice President, Finance and Treasurer | -- | 未披露 | 未持股 | 2025-12-11 |
| Paul T. Quinlan | -- | General Counsel and Corporate Secretary | -- | 233.86万美元 | 1.02 | 2025-12-11 |
董事简历
中英对照 | 中文 | 英文- Lawrence Otto Klein
-
劳伦斯·奥托·克莱因自2024年7月起担任董事会成员。Klein博士自2024年8月起担任生物技术公司Oruka Therapeutics，Inc.（前身为ARCA BioPharma，Inc.）（纳斯达克：ORKA）（“Oruka”）的首席执行官和董事会成员，并自2024年2月起至2024年8月完成该公司与Oruka的BINCE合并期间担任一家前身为Oruka Therapeutics，Inc.的私营生物技术公司的首席执行官和董事会成员。从2023年1月到2024年2月，Klein博士是Versant Venture Management，LLC（“Versant”）的合伙人，该公司是一家医疗保健和生物技术风险投资公司。在加入Versant之前，Klein博士曾在生物制药公司CRISPR Therapeutics AG（纳斯达克：CRSP）担任多个职位，包括2020年1月至2022年10月的首席运营官、2019年1月至2020年1月的首席BINSER官、2017年11月至2018年12月的BINSER发展和战略高级副总裁以及2016年2月至2017年11月的战略副总裁。在加入CRISPR之前，Klein博士曾于2014年10月至2016年2月在全球管理咨询公司麦肯锡公司担任副合伙人。Klein博士于2019年9月至2023年5月担任Dyne Therapeutics, Inc.（纳斯达克：DYN）的董事会成员，并于2021年9月至2023年6月担任Jasper Therapeutics, Inc.（纳斯达克：JSPR）的董事会成员。Klein博士在威斯康星大学麦迪逊分校获得生物化学和物理学学士学位，在斯坦福大学获得生物物理学博士学位。
Lawrence Otto Klein has served as a member of Board since July 2024. Dr. Klein has served as Chief Executive Officer and as a member of the board of directors of Oruka Therapeutics, Inc. (formerly known as ARCA biopharma, Inc.) (Nasdaq: ORKA) ("Oruka"), a biotechnology company, since August 2024, and served as Chief Executive Officer and as a member of the board of directors of a private biotechnology company formerly known as Oruka Therapeutics, Inc. from February 2024 through the completion of the company's biness combination with Oruka in August 2024. From January 2023 to February 2024, Dr. Klein was a Partner at Versant Venture Management, LLC ("Versant"), a healthcare and biotechnology venture capital firm. Prior to Versant, Dr. Klein served in vario positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January 2020 to October 2022, Chief Biness Officer from January 2019 to January 2020, Senior Vice President, Biness Development and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017. Before joining CRISPR, Dr. Klein was an Associate Partner at McKinsey & Company, a global management consulting firm, from October 2014 to February 2016. Dr. Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September 2019 to May 2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September 2021 to June 2023. Dr. Klein received his B.S. in Biochemistry and Physics from the University of Wisconsin Madison and his Ph.D. in Biophysics from Stanford University. - 劳伦斯·奥托·克莱因自2024年7月起担任董事会成员。Klein博士自2024年8月起担任生物技术公司Oruka Therapeutics，Inc.（前身为ARCA BioPharma，Inc.）（纳斯达克：ORKA）（“Oruka”）的首席执行官和董事会成员，并自2024年2月起至2024年8月完成该公司与Oruka的BINCE合并期间担任一家前身为Oruka Therapeutics，Inc.的私营生物技术公司的首席执行官和董事会成员。从2023年1月到2024年2月，Klein博士是Versant Venture Management，LLC（“Versant”）的合伙人，该公司是一家医疗保健和生物技术风险投资公司。在加入Versant之前，Klein博士曾在生物制药公司CRISPR Therapeutics AG（纳斯达克：CRSP）担任多个职位，包括2020年1月至2022年10月的首席运营官、2019年1月至2020年1月的首席BINSER官、2017年11月至2018年12月的BINSER发展和战略高级副总裁以及2016年2月至2017年11月的战略副总裁。在加入CRISPR之前，Klein博士曾于2014年10月至2016年2月在全球管理咨询公司麦肯锡公司担任副合伙人。Klein博士于2019年9月至2023年5月担任Dyne Therapeutics, Inc.（纳斯达克：DYN）的董事会成员，并于2021年9月至2023年6月担任Jasper Therapeutics, Inc.（纳斯达克：JSPR）的董事会成员。Klein博士在威斯康星大学麦迪逊分校获得生物化学和物理学学士学位，在斯坦福大学获得生物物理学博士学位。
- Lawrence Otto Klein has served as a member of Board since July 2024. Dr. Klein has served as Chief Executive Officer and as a member of the board of directors of Oruka Therapeutics, Inc. (formerly known as ARCA biopharma, Inc.) (Nasdaq: ORKA) ("Oruka"), a biotechnology company, since August 2024, and served as Chief Executive Officer and as a member of the board of directors of a private biotechnology company formerly known as Oruka Therapeutics, Inc. from February 2024 through the completion of the company's biness combination with Oruka in August 2024. From January 2023 to February 2024, Dr. Klein was a Partner at Versant Venture Management, LLC ("Versant"), a healthcare and biotechnology venture capital firm. Prior to Versant, Dr. Klein served in vario positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January 2020 to October 2022, Chief Biness Officer from January 2019 to January 2020, Senior Vice President, Biness Development and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017. Before joining CRISPR, Dr. Klein was an Associate Partner at McKinsey & Company, a global management consulting firm, from October 2014 to February 2016. Dr. Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September 2019 to May 2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September 2021 to June 2023. Dr. Klein received his B.S. in Biochemistry and Physics from the University of Wisconsin Madison and his Ph.D. in Biophysics from Stanford University.
- Samarth Kulkarni
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kristine M. Ball
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Peter Harwin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Carl Dambkowski
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Christopher Martin
-
Christopher Martin，于2024年1月至2025年10月在维罗纳制药担任首席商务官，该公司于2025年10月被默沙东公司以约100亿美元的价格收购。作为首席商务官，Martin先生负责构建公司首个产品发布Ohtuvayre的商业组织和发布策略（ensifentrine）。Martin先生此前曾担任维罗纳的其他管理职位，包括2022年1月至2023年12月的商务高级副总裁，以及2020年6月和2022年12月的商务副总裁。此前，他曾于2018年3月至2020年6月在SK Life Science担任市场营销执行总监，该公司专注于开发针对中枢神经系统疾病的新型疗法。Martin先生在制定商业和营销战略以及推出他们的第一个商业产品XCOPRI的框架方面发挥了重要作用（cenobamate片）。在被Melinta Therapeutics收购之前，Martin先生是Cempra的营销主管，在那里他领导了该公司第一个产品索利霉素的开发和发布战略。在加入Cempra之前，他曾在柳药医疗任职10年，担任与日俱增的职责，并领导了Xifaxan公司被Valeant Pharmaceuticals收购期间的营销团队。Martin先生获得了克莱姆森大学财务管理理学学士学位。
Christopher Martin,served as Chief Commercial Officer from January 2024 to October 2025 for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October 2025. As Chief Commercial Officer, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre (ensifentrine). Mr. Martin previously served in other management positions at Verona, including Senior Vice President of Commercial from January 2022 to December 2023 and Vice President of Commercial from June 2020 and December 2022. Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions from March 2018 to June 2020. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University. - Christopher Martin，于2024年1月至2025年10月在维罗纳制药担任首席商务官，该公司于2025年10月被默沙东公司以约100亿美元的价格收购。作为首席商务官，Martin先生负责构建公司首个产品发布Ohtuvayre的商业组织和发布策略（ensifentrine）。Martin先生此前曾担任维罗纳的其他管理职位，包括2022年1月至2023年12月的商务高级副总裁，以及2020年6月和2022年12月的商务副总裁。此前，他曾于2018年3月至2020年6月在SK Life Science担任市场营销执行总监，该公司专注于开发针对中枢神经系统疾病的新型疗法。Martin先生在制定商业和营销战略以及推出他们的第一个商业产品XCOPRI的框架方面发挥了重要作用（cenobamate片）。在被Melinta Therapeutics收购之前，Martin先生是Cempra的营销主管，在那里他领导了该公司第一个产品索利霉素的开发和发布战略。在加入Cempra之前，他曾在柳药医疗任职10年，担任与日俱增的职责，并领导了Xifaxan公司被Valeant Pharmaceuticals收购期间的营销团队。Martin先生获得了克莱姆森大学财务管理理学学士学位。
- Christopher Martin,served as Chief Commercial Officer from January 2024 to October 2025 for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October 2025. As Chief Commercial Officer, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre (ensifentrine). Mr. Martin previously served in other management positions at Verona, including Senior Vice President of Commercial from January 2022 to December 2023 and Vice President of Commercial from June 2020 and December 2022. Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions from March 2018 to June 2020. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University.
高管简历
中英对照 | 中文 | 英文- Lawrence Otto Klein
劳伦斯·奥托·克莱因自2024年7月起担任董事会成员。Klein博士自2024年8月起担任生物技术公司Oruka Therapeutics，Inc.（前身为ARCA BioPharma，Inc.）（纳斯达克：ORKA）（“Oruka”）的首席执行官和董事会成员，并自2024年2月起至2024年8月完成该公司与Oruka的BINCE合并期间担任一家前身为Oruka Therapeutics，Inc.的私营生物技术公司的首席执行官和董事会成员。从2023年1月到2024年2月，Klein博士是Versant Venture Management，LLC（“Versant”）的合伙人，该公司是一家医疗保健和生物技术风险投资公司。在加入Versant之前，Klein博士曾在生物制药公司CRISPR Therapeutics AG（纳斯达克：CRSP）担任多个职位，包括2020年1月至2022年10月的首席运营官、2019年1月至2020年1月的首席BINSER官、2017年11月至2018年12月的BINSER发展和战略高级副总裁以及2016年2月至2017年11月的战略副总裁。在加入CRISPR之前，Klein博士曾于2014年10月至2016年2月在全球管理咨询公司麦肯锡公司担任副合伙人。Klein博士于2019年9月至2023年5月担任Dyne Therapeutics, Inc.（纳斯达克：DYN）的董事会成员，并于2021年9月至2023年6月担任Jasper Therapeutics, Inc.（纳斯达克：JSPR）的董事会成员。Klein博士在威斯康星大学麦迪逊分校获得生物化学和物理学学士学位，在斯坦福大学获得生物物理学博士学位。
Lawrence Otto Klein has served as a member of Board since July 2024. Dr. Klein has served as Chief Executive Officer and as a member of the board of directors of Oruka Therapeutics, Inc. (formerly known as ARCA biopharma, Inc.) (Nasdaq: ORKA) ("Oruka"), a biotechnology company, since August 2024, and served as Chief Executive Officer and as a member of the board of directors of a private biotechnology company formerly known as Oruka Therapeutics, Inc. from February 2024 through the completion of the company's biness combination with Oruka in August 2024. From January 2023 to February 2024, Dr. Klein was a Partner at Versant Venture Management, LLC ("Versant"), a healthcare and biotechnology venture capital firm. Prior to Versant, Dr. Klein served in vario positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January 2020 to October 2022, Chief Biness Officer from January 2019 to January 2020, Senior Vice President, Biness Development and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017. Before joining CRISPR, Dr. Klein was an Associate Partner at McKinsey & Company, a global management consulting firm, from October 2014 to February 2016. Dr. Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September 2019 to May 2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September 2021 to June 2023. Dr. Klein received his B.S. in Biochemistry and Physics from the University of Wisconsin Madison and his Ph.D. in Biophysics from Stanford University.- 劳伦斯·奥托·克莱因自2024年7月起担任董事会成员。Klein博士自2024年8月起担任生物技术公司Oruka Therapeutics，Inc.（前身为ARCA BioPharma，Inc.）（纳斯达克：ORKA）（“Oruka”）的首席执行官和董事会成员，并自2024年2月起至2024年8月完成该公司与Oruka的BINCE合并期间担任一家前身为Oruka Therapeutics，Inc.的私营生物技术公司的首席执行官和董事会成员。从2023年1月到2024年2月，Klein博士是Versant Venture Management，LLC（“Versant”）的合伙人，该公司是一家医疗保健和生物技术风险投资公司。在加入Versant之前，Klein博士曾在生物制药公司CRISPR Therapeutics AG（纳斯达克：CRSP）担任多个职位，包括2020年1月至2022年10月的首席运营官、2019年1月至2020年1月的首席BINSER官、2017年11月至2018年12月的BINSER发展和战略高级副总裁以及2016年2月至2017年11月的战略副总裁。在加入CRISPR之前，Klein博士曾于2014年10月至2016年2月在全球管理咨询公司麦肯锡公司担任副合伙人。Klein博士于2019年9月至2023年5月担任Dyne Therapeutics, Inc.（纳斯达克：DYN）的董事会成员，并于2021年9月至2023年6月担任Jasper Therapeutics, Inc.（纳斯达克：JSPR）的董事会成员。Klein博士在威斯康星大学麦迪逊分校获得生物化学和物理学学士学位，在斯坦福大学获得生物物理学博士学位。
- Lawrence Otto Klein has served as a member of Board since July 2024. Dr. Klein has served as Chief Executive Officer and as a member of the board of directors of Oruka Therapeutics, Inc. (formerly known as ARCA biopharma, Inc.) (Nasdaq: ORKA) ("Oruka"), a biotechnology company, since August 2024, and served as Chief Executive Officer and as a member of the board of directors of a private biotechnology company formerly known as Oruka Therapeutics, Inc. from February 2024 through the completion of the company's biness combination with Oruka in August 2024. From January 2023 to February 2024, Dr. Klein was a Partner at Versant Venture Management, LLC ("Versant"), a healthcare and biotechnology venture capital firm. Prior to Versant, Dr. Klein served in vario positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January 2020 to October 2022, Chief Biness Officer from January 2019 to January 2020, Senior Vice President, Biness Development and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017. Before joining CRISPR, Dr. Klein was an Associate Partner at McKinsey & Company, a global management consulting firm, from October 2014 to February 2016. Dr. Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September 2019 to May 2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September 2021 to June 2023. Dr. Klein received his B.S. in Biochemistry and Physics from the University of Wisconsin Madison and his Ph.D. in Biophysics from Stanford University.
- Laura Sandler
劳拉·桑德勒（Laura Sandler）自2024年3月起担任Oruka运营高级副总裁。在此之前，2023年9月至2024年3月，她在生物制药公司Kelonia Therapeutics，Inc.担任战略运营高级副总裁，负责项目领导、项目管理和质量保证。她于2022年7月至2023年8月担任独立生物制药顾问。在此之前，从2017年3月到2022年6月，Sandler女士在生物制药公司CRISPR Therapeutics AG担任过多个职位，最后担任开发运营高级副总裁，担任该公司临床执行和开发运营主管。从2013年9月到2017年3月，Sandler女士在生物制药公司bluebird bio公司领导LyfgeniaTM项目的开发运营团队。在她职业生涯的早期，她曾在Ventrus Biosciences Inc.、诺华、昆泰和MedImmune担任项目管理和临床运营方面的职务。桑德勒女士获得了波士顿大学公共卫生硕士学位，并获得了麻省理工学院的学士学位。
Laura Sandler,has served, since March 2024, as Oruka's Senior Vice President of Operations. Prior to that, from September 2023 to March 2024 she was Senior Vice President of Strategic Operations at Kelonia Therapeutics, Inc., a biopharmaceutical company, and was responsible for program leadership, program management, and quality assurance. She was an independent biopharmaceutical consultant from July 2022 to August 2023. Prior to that, from March 2017 to June 2022, Ms. Sandler held various positions at CRISPR Therapeutics AG, a biopharmaceutical company, ending as Senior Vice President of Development Operations, where she was the head of clinical execution and development operations for the company. From September 2013 to March 2017, Ms. Sandler led the development operations team for the LyfgeniaTM program at bluebird bio, Inc., a biopharmaceutical company. Earlier in her career, she held roles in project management and clinical operations at Ventrus Biosciences Inc., Novartis, Quintiles, and MedImmune. Ms. Sandler earned her master's degree in public health from Boston University and has a bachelor's degree from MIT.- 劳拉·桑德勒（Laura Sandler）自2024年3月起担任Oruka运营高级副总裁。在此之前，2023年9月至2024年3月，她在生物制药公司Kelonia Therapeutics，Inc.担任战略运营高级副总裁，负责项目领导、项目管理和质量保证。她于2022年7月至2023年8月担任独立生物制药顾问。在此之前，从2017年3月到2022年6月，Sandler女士在生物制药公司CRISPR Therapeutics AG担任过多个职位，最后担任开发运营高级副总裁，担任该公司临床执行和开发运营主管。从2013年9月到2017年3月，Sandler女士在生物制药公司bluebird bio公司领导LyfgeniaTM项目的开发运营团队。在她职业生涯的早期，她曾在Ventrus Biosciences Inc.、诺华、昆泰和MedImmune担任项目管理和临床运营方面的职务。桑德勒女士获得了波士顿大学公共卫生硕士学位，并获得了麻省理工学院的学士学位。
- Laura Sandler,has served, since March 2024, as Oruka's Senior Vice President of Operations. Prior to that, from September 2023 to March 2024 she was Senior Vice President of Strategic Operations at Kelonia Therapeutics, Inc., a biopharmaceutical company, and was responsible for program leadership, program management, and quality assurance. She was an independent biopharmaceutical consultant from July 2022 to August 2023. Prior to that, from March 2017 to June 2022, Ms. Sandler held various positions at CRISPR Therapeutics AG, a biopharmaceutical company, ending as Senior Vice President of Development Operations, where she was the head of clinical execution and development operations for the company. From September 2013 to March 2017, Ms. Sandler led the development operations team for the LyfgeniaTM program at bluebird bio, Inc., a biopharmaceutical company. Earlier in her career, she held roles in project management and clinical operations at Ventrus Biosciences Inc., Novartis, Quintiles, and MedImmune. Ms. Sandler earned her master's degree in public health from Boston University and has a bachelor's degree from MIT.
- Joana Goncalves
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Arjun Agarwal
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Paul T. Quinlan
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介